Henry Schein (HSIC) Completes Acquisition of Acentus

Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced it has completed the acquisition of substantially all of the assets of Acentus, a national medical supplier specializing in the delivery of Continuous Glucose Monitors (CGMs). Henry Schein announced the agreement to acquire Acentus on November 20, 2024.

Headquartered in Tampa, Florida, Acentus reports annual revenue of approximately $35 million. Henry Schein expects the transaction to be neutral to 2025 non-GAAP earnings per share and accretive thereafter. Financial terms were not disclosed.

“Henry Schein continues to expand upon our national homecare solutions platform to effectively address the evolving needs of our customers, which includes clinics, physician practices, health systems, and patients receiving care at home,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, Henry Schein. “The acquisition of Acentus represents an important step towards strengthening our position within the home medical supply market. By directly delivering CGM products to patients’ homes, we are enhancing our ability to serve our valued customers and drive growth.”

The Acentus transaction follows Henry Schein’s acquisition of Prism Medical Products, LLC in 2021 and Shield Healthcare and Mini Pharmacy in 2023, reinforcing the Company’s strategic commitment to the homecare medical supplies market. Henry Schein’s homecare medical products platform will now have an annual revenue base in excess of $350 million.

Acentus Founders Brett Carroll, Todd Cianfrocca, Greg Duvall, and Julio Valdivia will join Henry Schein and bring their expertise and experience in the product category and the health care industry.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Spin Master agrees to acquire Brooklyn-based Hapiko Inc.
• Baosheng Media signs MOU to acquire 40% stake in AI marketing firm